Improving stroke prevention in patients with atrial fibrillation (AF) is of paramount clinical importance 1 . Although oral anticoagulation (OAC) currently remains the mainstay of stroke preventive therapy in AF, there is a significant group of patients who cannot tolerate long-term anticoagulation treatment, largely due to an increased bleeding risk. For these patients in particular, left atrial appendage occlusion (LAAO) is being developed further as an alternative mode of stroke/embolism prevention.
Since 2001, the year in which Horst Sievert, assisted by Michael Lesh, performed the first catheter-based LAAO using the percutaneous left atrial appendage transcatheter occlusion (PLAATO; ev3 Endovascular, Plymouth, MN, USA) device, and 2002 when Bernhard Meier used an Amplatzer™ device (St. Jude Medical, St. Paul, MN, USA) for the first time, significant progress in LAAO devices and implantation techniques has been achieved. In addition, it has become increasingly important to provide educational and scientific support to ensure optimal LAAO. The state of the art in this field is very nicely provided in the 2019 EHRA/ EAPCI consensus statement update. This document highlights the importance of operator training and centre readiness for LAAO programmes, describes in detail recommended implantation and management approaches for these patients, and emphasises the important role of different cardiovascular imaging modalities in pre-, peri-and post-interventional management 2 .
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Non-vitamin K antagonists (NOACs) have now been introduced into clinical practice [3] [4] [5] , providing an improved stroke prevention approach in AF patients. However, in large-scale randomised phase III clinical studies, adherence rates for NOACs after 24 months have been shown to be around 67-79%, i.e., >20% may not tolerate this therapy long term under clinical trial conditions [3] [4] [5] . The main reasons for discontinuation included major bleeding, renal insufficiency and a perceived high bleeding risk. While NOACs significantly reduce the risk of intracranial bleeding as compared to the vitamin K antagonist warfarin, major bleedings still occur at a rate of 2-3% per year, despite the fact that important groups of patients were excluded from the phase III NOAC trials based on a perceived high bleeding risk [3] [4] [5] . Accordingly, there is a particular important clinical need for stroke prevention in patients with AF who cannot tolerate long-term oral anticoagulation therapy [6] [7] [8] .
In 2016 >13,000 percutaneous LAA occlusions were performed worldwide, illustrating the current need for further advice on the optimised procedural aspects which has been provided in the well-timed consensus statement. However, in contrast to Europe where, due to data from large LAAO registries, several CE-marked devices are used in particular for patients noneligible for long-term OAC 1 , in 2015, the FDA approved the WATCHMAN™ (Boston Scientific, Marlborough, MA, USA) as the only device in the USA as an alternative to OAC, since the only randomised study was performed in patients eligible for warfarin therapy.
The efficacy and safety of LAAO have been analysed in two randomised studies and large-scale prospective observational registries. Additionally, safety will be considerably improved by optimal training of implanters, centre experience and the introduction of improved implantation techniques and LAA occlusion devices. At present, the peri-interventional complication rate is down to less than three percent in experienced centres.
In this issue of EuroIntervention, Glikson et al summarise the scientific background and rationale for the procedure, give a summary and critical appraisal of the available scientific evidence regarding LAAO, define the procedural pitfalls, formulate the requirements for implementation of a structured LAAO programme, characterise indications, and provide an outlook on the currently ongoing controlled randomised clinical studies 2 .
In the present document a careful and systematic review of the new clinical knowledge base on LAA is provided (Figure 1) . The 2019 EHRA/EAPCI consensus document update provides numerous recommendations for LAAO. It also acknowledges that further data from randomised clinical trials in different patient populations will provide an important rationale for optimal management in AF patients with a high bleeding risk. Of note, in the field of PFO closure, in 2017 several large-scale randomised trials with longer follow-up provided consistent evidence that the procedure is safe and effective in appropriate patients after TIA or stroke, which has resulted in an increasing clinical adaptation. The ongoing randomised clinical trials on catheter-based LAAO have the potential to have a similar impact on the field of LAAO.
Important takeaway messages and updates since the previous 2014 EHRA/EAPCI consensus document include the following: State of the art in LAAO cannot receive at least several weeks of any antiplatelet therapy. The risk of device-related thrombus formation and the treatment options are discussed. -Standards for the training of operators and centre readiness are given. -Ongoing studies and unanswered questions in the field are nicely reviewed. In summary, LAAO is becoming an increasingly important cardiac procedure and the EHRA/EAPCI consensus statement provides both a scientific update and a large amount of educational information with the aim of further improving the clinical outcomes of LAAO.
